Welcome to Iaso Therapeutics
Vaccines have protected humankind from many deadly infections including smallpox, yellow fever, and tetanus, saving millions of lives. However, the rampage of the COVID-19 over the world serves as a painful reminder of the lack of effective vaccines against many other diseases. Novel technologies that can be readily deployed for new vaccines, especially against newly emerged pathogens, are urgently needed.
Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases.
Mutant Qβ Platform
Iaso’s initial product offering is a disruptive new virus-like particle, mutant Qβ, that shows superiority in generating antibodies of interest when compared to conjugate carrier proteins like Keyhole Limpet Hemocyanin, diphtheria toxoid, tetanus toxoid, and cross reactive material-197 (CRM-197).
Company News
Building Better Vaccines: Iaso Therapeutics
Vaccines have dominated the news. With the COVID-19 pandemic, stories about vaccines have been a daily occurrence. They range from concerns about safety to vaccination rates and distribution. They highlight the amazing science that [...]
Iaso Therapeutics Invited to TRECS Workshop
East Lansing, MI – Iaso Therapeutics (Iaso) has received a selective invitation to participate in the National Cancer Institute (NCI) Translational Resources to Expedite Commercialization Success Workshop (TRECS WORKSHOP). Iaso will participate in the National [...]